At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 10 enrolled
Drug / intervention
TAK-954 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Sequence, Open-Label, 2-Period Crossover Trial to Evaluate the Effect of the Potent Cytochrome P-450 3A4 Inhibitor Itraconazole on the Pharmacokinetics of TAK-954 in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-954 and Itraconazole for Healthy Participants. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effect of the potent CYP3A4 inhibitor itraconazole on the single-dose PK of TAK-954.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartMay 2017
First PostedJun 2017
Primary CompletionJul 2017
TodayJul 2026
First PostedJun 1, 2017
Enrollment StartMay 31, 2017
Primary CompletionJul 24, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.1 years ago
Interventions
TAK-954drug
TAK-954 Infusion
Itraconazoledrug
Itraconazole Capsule